Laboratory and clinical studies on cefclidin in respiratory tract infections

Shigeru Kohno, Masanori Iwamoto, Kenichi Tanaka, Shigefumi Maesaki, Akira Yasuoka, Kazunori Shimokuchi, Hironobu Koga, Kohei Hara, Chikako Mochida, Kazuyuki Sugawara, Mitsuo Kaku, Toshiyuki Oe, Hideo Mashimoto, Naofumi Suyama, Sadahiro Asai, Koichi Watanabe, Tsuneo Tsutsumi

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Cefclidin (CFCL), a new cephem antibiotic, was basically and clinically evaluated to provide the following results: 1) Antimicrobial activity: CFCL exhibited excellent activity against not only the gram-positive cocci but the gram-negative rods, especially against Pseudomonas aeruginosa, Enterobacter cloacae and Citrobacter freundii. The activities of CFCL against Streptococcus pyogenes, Escherichia coli and Klebsiella pneumoniae were equal or superior to those of ceftazidime (CAZ) and the other reference drugs, however the activities against Streptococcus pneumoniae and Haemophilus influenzae were slightly inferior to those of other reference drugs. 2) CFCL concentrations in serum and sputum: 1 or 2 grams of CFCL was drip infused for 1 hour to two or one patients with chronic respiratory tract infection to measure its serum and sputum levels by bioassay, respectively. Peak serum levels were 58 and 45µg/ml in the 1 gram group and 137 µg/ml in the 2 gram patient at the end of drip infusion. Peak sputum levels were 2.0 and 2.84 µg/ml in the 1 gram group and 7.88 µg/ml in the 2 gram patient. 3) Clinical evaluation and adverse reactions: 44 patients (20 pneumonia, 1 chlamydia pneumonia, 3 pulmonary abscess, 1 lung cancer, 8 chronic bronchitis, 4 bronchiectasis, 7 diffuse panbronchiolitis) were treated with 2 grams daily of CFCL for 4-33 days. The clinical efficacy rate was 85.4% (pneumonia and pulmonary abscess 91.3%, chronic respiratory infection 77.8%). The bacteriological efficacy rate was 92.9%. Skin eruption in 2 patients, fever in 1, and squeeze feeling in 1 were observed. Mild aggravation in the liver function test was observed in 8 patients, eosinophilia in 4 (both in 2 patients), elevation of BUN in 1, and anemia in 3 patients. Most of these abnormalities disappeared after cessation of the treatment. We therefore conclude that CFCL is a useful antibiotic agent against bacterial respiratory infections.

Original languageEnglish
Pages (from-to)365-376
Number of pages12
JournalChemotherapy
Volume40
DOIs
Publication statusPublished - 1992 Sep
Externally publishedYes

Keywords

  • Cefclidin (CFCL)
  • MIC

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Infectious Diseases
  • Pharmacology
  • Drug Discovery
  • Oncology

Fingerprint Dive into the research topics of 'Laboratory and clinical studies on cefclidin in respiratory tract infections'. Together they form a unique fingerprint.

  • Cite this

    Kohno, S., Iwamoto, M., Tanaka, K., Maesaki, S., Yasuoka, A., Shimokuchi, K., Koga, H., Hara, K., Mochida, C., Sugawara, K., Kaku, M., Oe, T., Mashimoto, H., Suyama, N., Asai, S., Watanabe, K., & Tsutsumi, T. (1992). Laboratory and clinical studies on cefclidin in respiratory tract infections. Chemotherapy, 40, 365-376. https://doi.org/10.11250/chemotherapy1953.40.Supplement4_365